Establishing Clinical Utility Evidence for Chronic Disease Management Testing

Cardiometabolic Syndrome Clinical Trial

Official title:

Establishing Clinical Utility Evidence for Chronic Disease Management Testing (CDMT): A CPV® RandomizedControlled Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05192590
• Other study ID #: Pro00057790
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 22, 2021
• Est. completion date: February 22, 2023

Study information

• Verified date: December 2022
• Source: Qure Healthcare, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a national-level research study of primary care physicians. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.

Description:

The results of this study could contribute to improved quality of care for patients by encouraging better care practices and adherence to evidence-based guidance. The data from this study will be submitted to a national journal for publication. The study plans to enroll up to 300 physicians. Upon consenting and agreeing to participate in this study, participants will be asked to care for 3 simulated patient cases, known as Clinical Performance and Value Vignettes (CPV®). CPVs describe patients physicians typically encounter in their daily practice and are not meant to be difficult. In each vignette, physicians are asked to share their expected care through 5 domains: 1) history, 2) physical exam, 3) diagnostic workup, 4) diagnosis and 5) treatment and follow-up. Each case takes approximately 15-20 minutes to complete and we estimate the time commitment for each round of CPV administration to be approximately 45 - 60 minutes. All responses to the cases will be completed online and will be kept confidential. Over 2 CPV administration rounds, the total time to care for the simulated patients is estimated at 1.5-2 hours. If physicians are randomized to an intervention group in this study, they will receive education materials on a diagnostic test currently available for use in the market after the first round of CPV administration. They are asked to review these materials before moving to the next CPV administration round. Time to review education materials is estimated to be approximately 15 minutes. Depending on the results of this randomized controlled trial, there may be an opportunity for physicians to re-enroll into a follow-on study. If they choose to participate in this second study, they will be asked to identify and send de-identified records of patients in their practice that are similar to the simulated patients they previously cared for in this study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 249
• Est. completion date: February 22, 2023
• Est. primary completion date: February 21, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Subjects must meet the following criteria to be enrolled in the study:

1. Board-certified physician currently practicing in the following areas:

1. Internal medicine

2. Family medicine

2. Have practiced as a board-certified physician in internal or family medicine or greater than 2 but less than 30 years

3. Community / non-academic based practice setting

4. = 40 patients under care weekly

5. Commonly treats patients with atrial fibrillation, coronary artery disease, congestive heart failure, diabetes, hypertension, and hyperlipidemia

6. Practicing in the U.S.

7. English-speaking

8. Access to the internet

9. Informed and voluntarily consented to be in the study

Exclusion Criteria:

1. Non-English speaking

2. Practicing in an academic setting

3. Unable to access the internet

4. Not practicing in the U.S.

5. Do not voluntarily consent to be in the study

Related Conditions & MeSH terms

• Cardiometabolic Syndrome
• Chronic Disease
• Metabolic Syndrome

Intervention

Other:
• Educational Materials and Chronic Disease Management Test (CDMT)
Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the CDMT technology. These materials are comprised of a PowerPoint presentation. Intervention 1 participants only will receive the CDMT test results whether they select it or not, and Intervention 2 participants will receive the CDMT test results only if they select it during the second round of case simulations.

Locations

Country	Name	City	State
United States	QURE Healthcare	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Qure Healthcare, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CPV-measured clinical score difference(drug, procedures, counseling and other)	Difference-in-differences regression analysis between the control and the intervention groups' diagnosis and treatment of chronic dyspnea, as measured by the participants diagnostic and treatment CPV case domain scores. In each domain of a CPV (history, physical exam, workup, diagnosis and treatment), participants' care recommendations are evaluated against evidence-based care scoring criteria which can sum from 0 to a high potential score of up to 100 percent in each domain, where higher scores mean better outcomes.	12 months
Primary	Test Adoption Rate	Rate of adoption of the CDMT test in Intervention 2 arm participants.	12 months
Primary	CPV-measured cost difference	Difference in expected cost of care between control and intervention participants. (Cost will be calculated by measuring differential rates of medical interventions/levels of care selected by each arm, and multiplying by Medicare reimbursement rates for these interventions, and/or by modeling the incidence of expected complications and calculating associated costs.)	12 months
Secondary	CPV-measured clinical score differences by use case	Difference in the overall, and the diagnostic and treatment quality scores between control and intervention participants. Diagnostic and treatment scores are calculated as the percent correct on CPVs, and the overall score is a average score of the subcategory scores (percent correct). This will be examined for each of the use cases to determine in which case(s) CPV scores most improved.	12 months
Secondary	CPV-measured cost differences by use case	Difference in expected cost of care between control and intervention participants. (Cost will be calculated by measuring differential rates of medical interventions/levels of care selected by each arm, and multiplying by Medicare reimbursement rates for these interventions, and/or by modeling the incidence of expected complications and calculating associated costs.) This will be examined for each of the use cases to determine in which case(s) cost metrics most improved.	12 months
Secondary	CPV-measured baseline variation	Participants completing the simulated cases, or CPVs, receive scores based upon the quality of care they provide. This measure will assess the baseline levels of variation in the care of pain patients among all participants, including by use case types	12 months